• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶瘤病毒联合免疫疗法的文献计量分析。

A bibliometric analysis of oncolytic virotherapy combined with immunotherapy.

机构信息

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Hum Vaccin Immunother. 2024 Dec 31;20(1):2406621. doi: 10.1080/21645515.2024.2406621. Epub 2024 Oct 14.

DOI:10.1080/21645515.2024.2406621
PMID:39400287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485904/
Abstract

Oncolytic virotherapy in combination with immunotherapy has demonstrated significant survival benefits in some types of cancer. Here, we summarized the development, research hotpots and potential trends of the combination therapy using visual bibliometric analysis. A total of 712 articles were retrieved on June 21, 2023. The USA was the top contributors of any country (325, 45.65%), and the Rluk Research Libraries UK ranked first (43, 6.03%) of any institutions. The Journal for ImmunoTherapy of Cancer was with the largest publications (60, 8.43%). 'Tumor microenvironment' and 'delivery' were citation keywords with the strongest ongoing bursts. Research fronts in the future may focus on the methods of virus delivery and tumor microenvironment modulation. Futhermore, the most extensively studied cancer were melanoma, glioma and hepatocellular carcinoma.

摘要

溶瘤病毒治疗联合免疫治疗在某些类型的癌症中显示出显著的生存获益。在这里,我们通过可视化文献计量分析总结了该联合治疗的发展、研究热点和潜在趋势。于 2023 年 6 月 21 日检索到了 712 篇文章。美国是任何国家(325,45.65%)中发文量最多的国家,而 Rluk 研究图书馆英国(43,6.03%)是任何机构中发文量最多的机构。《癌症免疫治疗杂志》的发文量最大(60,8.43%)。“肿瘤微环境”和“递送”是引文关键词中具有最强持续爆发的两个关键词。未来的研究前沿可能集中在病毒递送和肿瘤微环境调节的方法上。此外,研究最多的癌症是黑色素瘤、神经胶质瘤和肝细胞癌。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/57f8c544d522/KHVI_A_2406621_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/865b05fc328e/KHVI_A_2406621_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/166ca4862b1f/KHVI_A_2406621_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/917308552216/KHVI_A_2406621_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/57f8c544d522/KHVI_A_2406621_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/865b05fc328e/KHVI_A_2406621_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/166ca4862b1f/KHVI_A_2406621_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/917308552216/KHVI_A_2406621_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b5b/11485904/57f8c544d522/KHVI_A_2406621_F0004_OC.jpg

相似文献

1
A bibliometric analysis of oncolytic virotherapy combined with immunotherapy.溶瘤病毒联合免疫疗法的文献计量分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2406621. doi: 10.1080/21645515.2024.2406621. Epub 2024 Oct 14.
2
Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.溶瘤病毒治疗中枢神经系统肿瘤的研究热点和趋势:文献计量学研究。
Front Immunol. 2022 Sep 6;13:975695. doi: 10.3389/fimmu.2022.975695. eCollection 2022.
3
Integrating oncolytic viruses in combination cancer immunotherapy.将溶瘤病毒整合到联合癌症免疫疗法中。
Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6.
4
Current perspectives and trends of CD39-CD73-eAdo/A2aR research in tumor microenvironment: a bibliometric analysis.肿瘤微环境中 CD39-CD73-eAdo/A2aR 研究的现状和趋势:文献计量学分析。
Front Immunol. 2024 Aug 12;15:1427380. doi: 10.3389/fimmu.2024.1427380. eCollection 2024.
5
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.恶性脑胶质瘤溶瘤病毒治疗的临床现状、挑战与未来方向的更新。
Curr Treat Options Oncol. 2024 Jul;25(7):952-991. doi: 10.1007/s11864-024-01211-6. Epub 2024 Jun 19.
6
Role of NK cells in immunotherapy and virotherapy of solid tumors.自然杀伤细胞在实体瘤免疫治疗和病毒治疗中的作用。
Immunotherapy. 2015;7(8):861-82. doi: 10.2217/imt.15.53. Epub 2015 Aug 28.
7
A bibliometric review of oncolytic virus research as a novel approach for cancer therapy.肿瘤溶瘤病毒治疗研究的文献计量学评价:一种癌症治疗的新方法。
Virol J. 2021 May 12;18(1):98. doi: 10.1186/s12985-021-01571-7.
8
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.通过联合肿瘤溶瘤病毒治疗方案提高抗肿瘤疗效。
Mol Cancer. 2020 Nov 10;19(1):158. doi: 10.1186/s12943-020-01275-6.
9
Oncolytic Immunotherapy for Treatment of Cancer.溶瘤免疫疗法治疗癌症
Adv Exp Med Biol. 2016;909:241-83. doi: 10.1007/978-94-017-7555-7_5.
10
A promising future in cancer immunotherapy: Oncolytic viruses.癌症免疫疗法的光明前景:溶瘤病毒。
Eur J Pharmacol. 2023 Dec 5;960:176063. doi: 10.1016/j.ejphar.2023.176063. Epub 2023 Oct 4.

引用本文的文献

1
Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment (Review).结直肠癌的精准溶瘤病毒疗法:用于个性化治疗的基因靶向和免疫调节(综述)
Int J Mol Med. 2025 Jul;56(1). doi: 10.3892/ijmm.2025.5545. Epub 2025 May 9.

本文引用的文献

1
Oncolytic virotherapy: basic principles, recent advances and future directions.溶瘤病毒治疗:基本原则、最新进展和未来方向。
Signal Transduct Target Ther. 2023 Apr 11;8(1):156. doi: 10.1038/s41392-023-01407-6.
2
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.工程策略增强溶瘤病毒在癌症免疫治疗中的作用。
Signal Transduct Target Ther. 2022 Apr 6;7(1):117. doi: 10.1038/s41392-022-00951-x.
3
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
CheckMate 017 和 057 随机、III 期临床试验的 5 年结果:纳武利尤单抗对比多西他赛用于先前治疗的非小细胞肺癌。
J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15.
4
Research hotspots and effectiveness of repetitive transcranial magnetic stimulation in stroke rehabilitation.重复经颅磁刺激在脑卒中康复中的研究热点与疗效
Neural Regen Res. 2020 Nov;15(11):2089-2097. doi: 10.4103/1673-5374.282269.
5
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
6
The Tumor Microenvironment Innately Modulates Cancer Progression.肿瘤微环境先天调节癌症进展。
Cancer Res. 2019 Sep 15;79(18):4557-4566. doi: 10.1158/0008-5472.CAN-18-3962. Epub 2019 Jul 26.
7
Optimizing oncolytic virotherapy in cancer treatment.优化溶瘤病毒治疗癌症。
Nat Rev Drug Discov. 2019 Sep;18(9):689-706. doi: 10.1038/s41573-019-0029-0. Epub 2019 Jul 10.
8
Delivery technologies for cancer immunotherapy.癌症免疫疗法的递药技术。
Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z.
9
Cancer immunoediting and resistance to T cell-based immunotherapy.癌症免疫编辑与 T 细胞免疫疗法抵抗。
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8.
10
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer.核因子-κB c-Rel对癌症中的调节性T细胞免疫检查点至关重要。
Cell. 2017 Sep 7;170(6):1096-1108.e13. doi: 10.1016/j.cell.2017.08.004.